Call for pull incentives to get startedWith new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality. more ➔
ADC Therapeutics: US$325m for ADC royaltie...ADC Therapeutics is set to receive up to US$325m for a royalty share in its antibody drug conjugates Zynlonta and Cami. more ➔
Cardior bags €64m in Series B FinancingCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure. more ➔
Yet another blow to Merck’s cancer h...GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results. more ➔
Beckley Psytech: €68m for psychedelic me...UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing … more ➔
ERS Genomics and Cellular Engineering Tech...ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement. more ➔
Boehringer walks away from CureVac dealSetback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company. more ➔
New vaccine trial targets Covid variantsVaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001. more ➔
Visus Therapeutics cashes in €20m from L...Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia more ➔
Protein may help control cancer cellsThe protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find. more ➔
